Indian Biotech Company Biocon on 26 November 2013 announced that it had received market authorisation from the Drug Controller General of India (DCGI) for its Breast cancer Drug- biosimilar Trastuzumab.
The biosimilar trastuzumab will be marketed in India under the brand name of CANMAb by the company, and is expected to be available to Indian patients in the fourth quarter of FY14. The drug is jointly developed by Biocon along with US-based pharma company Mylan.
Breast cancer is one of the most common types of cancer in India, with over 100000 new patients being diagnosed with this disease every year. The cost of biologics in cancer treatment is high, which makes access unaffordable to a large number of patients.
Biosimilar Trastuzumab will offer an alternative affordable option thereby enhancing access to treatment for cancer patients in India and the world over.
Biosimilar Trastuzumab drug is used for the treatment of Her 2+ metastatic breast cancer.The Biosimilar Trastuzumab marketed in the brand name of CANMab. CANMab is the first biological equivalent of Herceptin, a breast cancer drug manufactured by Swiss company, Roche.
Who: Bicon and Mylan
When: 26 November2013
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.